Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab-Reference-Cited by-同舟云学术

Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab

Published:2022-08-17 Issue: Volume: Page:
ISSN:1976-2283
Container-title:Gut and Liver
language:en
Short-container-title:Gut and Liver

Author:

Park Jihye¹^ORCID,Cheon Jae Hee¹^ORCID,Lee Kang-Moon²^ORCID,Kim Young-Ho³^ORCID,Ye Byong Duk⁴^ORCID,Eun Chang Soo⁵^ORCID,Kim Sung Hyun⁶^ORCID,Lee Sun Hee⁶^ORCID,Lee Joon Ho⁶^ORCID,Schreiber Stefan⁷^ORCID

Affiliation:

1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

2. Department of Internal Medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea

3. Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

4. Department of Gastroenterology and Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Seoul, Korea

5. Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea

6. Medical Science Division, Celltrion, Inc., Incheon, Korea

7. Department of Internal Medicine I, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany

Publisher

The Editorial Office of Gut and Liver

Subject

Gastroenterology,Hepatology

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low muscle mass is associated with efficacy of biologics in Crohn's disease;Clinical Nutrition;2024-10

2. Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease;Frontiers in Pharmacology;2024-08-27

3. Evaluating the Efficacy of Infliximab in Inflammatory Bowel Disease: A Systematic Review of the Literature;Cureus;2024-08-01

4. Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology;Therapeutic Drug Monitoring;2024-04-17